胰淀素类似物普兰林肽可诱发无先兆偏头痛患者的偏头痛样发作
人受体药理学研究提示胰淀素受体而非经典CGRP受体介导该效应,支持双重拮抗策略。
要点
- 普兰林肽可诱发偏头痛样发作,临床特征与CGRP诱发者相似。
- 普兰林肽诱发头痛88%、偏头痛样发作41%,与CGRP组无显著差异。
- 胰淀素受体可能介导该效应,双重拮抗或优于单纯CGRP受体阻断。
核心结论
- 胰淀素受体激动可能是偏头痛发病的新机制,双重拮抗胰淀素和CGRP受体或带来更大治疗获益。
研究设计与样本
- 辅以细胞、小鼠模型及大鼠、小鼠和人类组织样本的转化研究。
主要发现
- 普兰林肽诱发的偏头痛样发作临床特征与CGRP诱发者相似,但血管参数存在组间差异。
- 人受体药理学研究提示胰淀素受体而非经典CGRP受体介导普兰林肽效应。
- 临床前实验显示胰淀素与CGRP类似,可引起小鼠皮肤超敏和畏光。
关键数值与推荐
- 头痛发生率组间比较p = 0.375,偏头痛样发作发生率组间比较p = 0.180。
临床怎么用
- 提示胰淀素受体是偏头痛的潜在治疗靶点,未来可探索双重拮抗胰淀素和CGRP受体的策略。
- 普兰林肽诱发的偏头痛样发作特征与CGRP相似,临床评估偏头痛触发因素时需考虑胰淀素通路。
局限性
- 研究对象为无先兆偏头痛患者,结果外推至其他偏头痛亚型需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Migraine is a prevalent and disabling neurological disease. Its genesis is poorly understood, and there remains unmet clinical need. We aimed to identify mechanisms and thus novel therapeutic targets for migraine using human models of migraine and translational models in animals, with emphasis on amylin, a close relative of calcitonin gene-related peptide (CGRP). METHODS: Thirty-six migraine without aura patients were enrolled in a randomized, double-blind, 2-way, crossover, positive-controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on 2 different experimental days. Furthermore, translational studies in cells and mouse models, and rat, mouse and human tissue samples were conducted. RESULTS: Thirty patients (88%) developed headache after pramlintide infusion, compared to 33 (97%) after CGRP (p = 0.375). Fourteen patients (41%) developed migraine-like attacks after pramlintide infusion, compared to 19 patients (56%) after CGRP (p = 0.180). The pramlintide-induced migraine-like attacks had similar clinical characteristics to those induced by CGRP. There were differences between treatments in vascular parameters. Human receptor pharmacology studies showed that an amylin receptor likely mediates these pramlintide-provoked effects, rather than the canonical CGRP receptor. Supporting this, preclinical experiments investigating symptoms associated with migraine showed that amylin treatment, like CGRP, caused cutaneous hypersensitivity and light aversion in mice. INTERPRETATION: Our findings propose amylin receptor agonism as a novel contributor to migraine pathogenesis. Greater therapeutic gains could therefore be made for migraine patients through dual amylin and CGRP receptor antagonism, rather than selectively targeting the canonical CGRP receptor. ANN NEUROL 2021;89:1157-1171.
引用
- Ghanizada H, Al-Karagholi MA, Walker CS, et al. Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients. Ann Neurol. 2021. PMID: 33772845. doi:10.1002/ana.26072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。